Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
clinical trials
9
×
life sciences
national blog main
fda
boston blog main
boston top stories
national top stories
europe top stories
san francisco top stories
boston
europe blog main
national
new york top stories
san francisco blog main
abbvie
allergan
cancer
drug development
drugs
innovation
new york blog main
san diego blog main
san diego top stories
texas blog main
texas top stories
ucla
venture capital
abaloparatide
access biotechnology
access industries
akcea therapeutics
al guillem
alkermes
alnylam pharmaceuticals
amgen
anemia
arena pharmaceuticals
astrazeneca
atlas ventures
What
medicine
9
×
drug
fda
patients
clinical
friday
marketing
million
new
therapy
trial
weight
advance
agent
ago
alkermes
allergan
alnylam
amgen
amgen’s
anemia
antipsychotic
approval
approve
approved
atrophy
awaits
benefits
better
biologic
biological
blessing
blood
body
bosley
bottleneck
cancer
carries
carry
caveats
Language
unset
Current search:
medicine
×
" clinical trials "
×
biotech
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority
@xconomy.com
6 years ago
OncoNano, Maker of Tumor Imaging Technology, Raises $11.7 Million